GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » EBIT per Share

Serina Therapeutics (Serina Therapeutics) EBIT per Share : $-0.97 (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics EBIT per Share?

Serina Therapeutics's EBIT per Share for the six months ended in Mar. 2024 was $-1.09. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.97.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Serina Therapeutics's EBIT per Share or its related term are showing as below:

SER's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Serina Therapeutics's EBIT for the six months ended in Mar. 2024 was $-9.34 Mil.

Serina Therapeutics EBIT per Share Historical Data

The historical data trend for Serina Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics EBIT per Share Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22
EBIT per Share
-0.15 -0.31

Serina Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Mar24
EBIT per Share - -0.17 -0.15 0.12 -1.09

Serina Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Serina Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBIT per Share(A: Dec. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.666/8.569
=-0.31

Serina Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

EBIT per Share(Q: Mar. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-9.338/8.569
=-1.09

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics  (AMEX:SER) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Serina Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » EBIT per Share
Comparable Companies
Traded in Other Exchanges
2BO:Germany
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Website
https://www.serinatherapeutics.com
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024